+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 90Years
All Genders
ID05636618

First-in-Human Study of 212PbVMT--NET Targeted Alpha Therapy for Advanced SSTR2 Positive Tumors Evaluating Dose and Safety

Led by Perspective Therapeutics · Updated on 2026-10-13

300

Participants Needed

20

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a new targeted alpha-particle therapy called 212PbVMT--NET for adults with advanced somatostatin receptor type 2 SSTR2 positive tumors, including neuroendocrine tumors NETs, meningioma, pheochromocytoma, and paragangliomas. This Phase IIIa open-label study aims to find the best radioactive dose that balances safety and effectiveness, especially for patients who have not previously received peptide receptor radionuclide therapy PRRT. Participants will receive intravenous infusions of 212PbVMT--NET in two study parts first, a dose-finding phase with up to four administrations about eight weeks apart to identify the optimal dose second, a dose-expansion phase where a recommended dose is further assessed for safety and initial effectiveness. All subjects will also receive reno-protective amino acids to protect kidney function. A dosimetry sub-study using 203PbVMT--NET will measure radiation distribution before treatment. Throughout the study, participants will undergo imaging scans, laboratory tests, and clinical evaluations to monitor tumor response, adverse events, and overall safety for up to three years after treatment ends. The research team will assess dose-limiting toxicities, tumor shrinkage using established criteria, progression-free survival, and pharmacokinetics. Participants are expected to comply with study visits, treatments, and safety monitoring during this extended period.

CONDITIONS

Brief Title

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors

Research Team

C

ClinicalTrials at Perspectivetherapeutics

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here